Overview

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Status:
Not yet recruiting

Trial end date:
2026-09-28

Target enrollment:

Participant gender:

Summary

The objective of this study is to evaluate the efficacy of FORE8394 in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harboring BRAF fusions, or in participants with recurrent high-grade glioma (HGG) harboring BRAF V600E mutation. This will be conducted as two single arm open-label subprotocols (F8394-201A; F8394-201B) under one master protocol.

Phase:

Phase 2

Details

Lead Sponsor:

Fore Biotherapeutics

Treatments:

Cobicistat